
Opinion|Videos|July 29, 2024
Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance?
- In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
NIH F32 Grants Boost Early-Career Researchers’ Success
4
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
5














































